Argenx agreed on November 9, 2026 to buy Unnatural Products for $550 million upfront, up to about $1.15 billion, adding an AI guided oral macrocycle platform.
Last updated: November 10, 2026
Argenx will acquire Santa Cruz based Unnatural Products for $550 million in cash upfront plus contingent value rights tied to development and regulatory milestones, a total potential value of up to approximately $1.15 billion. The deal adds oral macrocyclic peptide discovery to an antibody company and is expected to close by year end.
Scope: the argenx deal terms, Vir’s first trading session after its Phase 3 hepatitis delta result, the FDA’s Not Approvable Letter for Novocure’s Optune Mya, Veradermics’ 12 month Study 302 data, and the Zolgensma tumor disclosures from late last week, with settled closes from Monday, November 9.
What is argenx paying for Unnatural Products?
Argenx is paying $550 million upfront for all of the outstanding equity of Unnatural Products (UNP), plus contingent value rights that bring the total potential value to up to approximately $1.15 billion, according to the companies’ November 9 release. Closing is expected by year end, subject to customary conditions.
The release does not split the contingent payments. BioPharma Dive reports the milestones at up to $595 million, which squares with the headline total: $550 million plus $595 million is $1.145 billion by our arithmetic. The release describes the contingent value rights as tied to development and regulatory milestones and does not say which programs or events trigger them.
| Deal component | Figure | Source |
|---|---|---|
| Upfront cash | $550 million | Company release |
| Contingent value rights | Up to $595 million | BioPharma Dive (release gives no split) |
| Total potential value | Up to approximately $1.15 billion | Company release |
| What is acquired | All outstanding equity of UNP | Company release |
| Expected close | By year end 2026, customary conditions | Company release |
| Prior relationship | Research collaboration of more than two years; argenx held a minority stake | Release (collaboration); BioPharma Dive (stake) |
What does Unnatural Products do?
UNP develops orally delivered macrocyclic peptides aimed at targets that have been hard to drug. Its platform pairs AI guided design with massively parallel synthesis and direct to biology screening, which the company says lets it engineer drug like macrocycles repeatedly and at scale.
Macrocyclic peptides are ring shaped molecules larger than typical small molecules. The pitch, in the release’s words, is that they combine the precision of biologics with the convenience of oral dosing. That is the strategic fit: argenx built its franchise on antibody engineering, led by Vyvgart (efgartigimod alfa), an injected and infused neonatal Fc receptor blocker, and UNP gives it a discovery route to pills against immune targets.
UNP was founded in 2016 by Cameron Pye and Joshua Schwochert during the final year of their doctoral work in Scott Lokey’s lab at the University of California, Santa Cruz. It has more than 50 employees and, per the release, signed four major pharma partnerships in under five years, naming Novartis, Merck and BridgeBio alongside argenx. After closing, the team stays in Santa Cruz as argenx’s dedicated macrocyclic peptide discovery hub. The release does not describe UNP’s ownership; BioPharma Dive describes it as venture funded.
Why would an antibody company buy an oral peptide platform?
Argenx is buying a discovery engine, not a late stage drug. The release frames UNP’s capabilities as complementary to antibody engineering, and argenx chief executive Karen Massey said UNP adds macrocyclic peptide capabilities that are “highly complementary to our antibody engineering.”
The financial context explains the appetite. BioPharma Dive cites argenx’s own disclosure of $4.5 billion in Vyvgart net product sales from January through September 2026. Leerink Partners analyst Thomas Smith, quoted by the same outlet, said the deal “signals further focus on pipeline growth and diversification.” It follows argenx’s earlier agreement to buy Forte Biosciences in a deal valued at up to $2.2 billion.
The deal also fits a pattern we have tracked all year: large companies with cash flow buying platforms outright while public investors decline to fund preclinical optionality. UNP never had to clear a public market price.
How did Vir trade after its Phase 3 hepatitis delta result?
Vir Biotechnology closed Monday at $13.645, up 11.8% from Friday’s $12.21, in the first full session after Sunday’s ECLIPSE 1 topline. The SPDR S&P Biotech ETF (XBI) rose 3.1% on the same day, so Vir outran the sector by roughly nine percentage points, all figures our arithmetic from settled closes.
ECLIPSE 1 tested the combination of elebsiran, a small interfering RNA, and tobevibart, a monoclonal antibody, in chronic hepatitis delta. Per Vir’s November 8 release, 44% of treated patients reached the primary endpoint of undetectable hepatitis delta RNA plus normal ALT at week 48, against 0% in the delayed treatment arm at week 12, with p below 0.0001. Vir plans a US regulatory submission in mid 2027 and expects data from ECLIPSE 2 and ECLIPSE 3 in the first quarter of 2027; the release does not state the application type.
Evercore ISI analyst Cory Kasimov, quoted by BioPharma Dive, wrote that the combination has the “potential to become a dominant front line product upon approval,” adding that “cross trial caveats apply, but the gap is wide.” The competitive set, per the same outlet, includes Gilead’s Hepcludex, approved in the US earlier this year, and Mirum’s brelovitug, which succeeded in the Phase 3 AZURE-1 study in September.
Why did the FDA reject Novocure’s Optune Mya?
The FDA issued a Not Approvable Letter on Novocure’s premarket approval application for Optune Mya, a Tumor Treating Fields device, in adults with brain metastases from non small cell lung cancer following stereotactic radiation. Novocure said the agency cited uncertainty about the degree of clinical benefit and did not raise safety concerns.
Novocure, in its November 9 release, said it is evaluating the feedback and plans to meet with the FDA to see whether any path to approval exists that would not require additional clinical studies, while cautioning there can be no assurance one does. A Not Approvable Letter is a device review action under the premarket approval pathway; it is not the same as a drug complete response letter.
MedTech Dive reports the application rested on the Phase 3 METIS trial, which delayed brain metastasis progression against best supportive care but showed no difference on secondary endpoints including neurocognitive failure, overall survival and radiological response. The outlet also reports that executive chairman William Doyle told investors in late October the company hoped for approval by year end and a launch in early 2027. Novocure shares closed at $12.53, down 5.6% on a day the XBI gained 3.1%, our arithmetic.
What did Veradermics report at 12 months in Study 302?
Veradermics reported 12 month results from Part B of Study 302 (NCT06724614) of VDPHL01, an extended release oral minoxidil, in men with mild to moderate pattern hair loss. Patients continuing twice daily 8.5 mg dosing gained 43.9 nonvellus hairs per square centimeter from baseline at month 12, and once daily patients gained 29.7.
The study randomized 519 men to 8.5 mg once daily, 8.5 mg twice daily or placebo for six months, after which placebo patients crossed over to VDPHL01. Because of the crossover, the release carries no placebo controlled comparison or p values at month 12. The company reported no treatment related serious adverse events and no adverse events of special interest of cardiac origin.
| Month 12 endpoint (Study 302 Part B) | Continued, twice daily | Continued, once daily | Placebo crossed, twice daily | Placebo crossed, once daily |
|---|---|---|---|---|
| Nonvellus hair count gain (hairs/cm²) | 43.9 | 29.7 | 32.1 | 24.5 |
| AAIRS improved or much improved | 68.0% | 48.4% | 60.7% | 42.9% |
| AAIRS any visible improvement | 89.1% | 79.8% | 82.0% | 73.2% |
| Investigator assessed improvement | 92.2% | 74.4% | 83.9% | 80.0% |
A vintage note: this is the 12 month Part B readout of Study 302. It is distinct from the six month Part A topline reported in April and from Study 304, which read out in October. The release does not give filing timing; data in women from Study 306 are expected in the first half of 2027. Veradermics shares closed at $143.95, up 3.7%, in line with the sector.
What did Novartis and the FDA say about tumors after Zolgensma?
According to BioPharma Dive, Novartis said on Thursday, November 5 that nine people with spinal muscular atrophy who received Zolgensma (onasemnogene abeparvovec) later developed tumors, and that two cases showed evidence the AAV delivery vector had integrated into patient DNA. Novartis said about 6,000 people have received the therapy.
The FDA said on Friday, November 6, per the same outlet, that it is investigating the cases and evaluating whether regulatory action is appropriate, while stating that benefits continue to outweigh potential risks for approved uses, and that the concern applies to the intrathecal product Itvisma as well. We could not retrieve either statement directly, so every figure here is attributed. For background on what the agency requires after gene therapy dosing, see our explainer on long term follow up below.
Which stock moves mattered on Monday, November 9?
| Ticker | Close | Change vs Friday | Why it matters |
|---|---|---|---|
| VIR | $13.645 | +11.8% | First full session after the ECLIPSE 1 pivotal win |
| NVCR | $12.53 | −5.6% | Not Approvable Letter for Optune Mya, against a rising sector |
| ARGX | $962.27 | +3.8% | Day of the Unnatural Products deal, in line with the sector |
| MANE | $143.95 | +3.7% | 12 month Study 302 data, in line with the sector |
| XBI / SPY | $156.90 / $752.69 | +3.1% / +2.4% | Context: a broad rally day |
Settled exchange closes; percentages are our arithmetic against Friday, November 6 closes.
Frequently asked questions
Who is acquiring Unnatural Products?
Argenx, the immunology company that markets Vyvgart, agreed on November 9, 2026 to acquire all of the outstanding equity of Unnatural Products.
How much is the argenx deal worth?
$550 million upfront in cash plus contingent value rights, for total potential value of up to approximately $1.15 billion, per the companies’ release.
What are the contingent value rights tied to?
Development and regulatory milestones, per the release, which does not name the programs. BioPharma Dive reports the rights at up to $595 million.
When will the argenx and Unnatural Products deal close?
By the end of 2026, subject to customary closing conditions, according to the release.
What are macrocyclic peptides?
Ring shaped peptide molecules designed to bind targets that small molecules struggle with, while potentially being taken by mouth rather than injected like antibodies.
Where is Unnatural Products based?
Santa Cruz, California. The company will keep operating there as argenx’s macrocyclic peptide discovery hub after closing.
How much did Vir stock rise after ECLIPSE 1?
Vir closed Monday, November 9 at $13.645, up 11.8% from Friday’s close, by our arithmetic from settled closes, versus a 3.1% gain for the XBI.
When will Vir file elebsiran and tobevibart with the FDA?
Vir plans a US regulatory submission in mid 2027, after ECLIPSE 2 and ECLIPSE 3 data expected in the first quarter of 2027. The application type has not been stated.
What is a Not Approvable Letter?
An FDA device review action on a premarket approval application stating that the application cannot be approved as submitted. Novocure received one for Optune Mya on November 9, 2026.
Why was Optune Mya not approved?
Novocure said the FDA cited uncertainty around the degree of clinical benefit and raised no safety concerns. The company plans to meet with the agency.
What is VDPHL01?
Veradermics’ extended release oral minoxidil for pattern hair loss, tested at 8.5 mg once or twice daily in men in Studies 302 and 304 and at 4.5 mg in women in Study 306.
How many hairs did VDPHL01 add at 12 months?
Men continuing twice daily dosing gained 43.9 nonvellus hairs per square centimeter from baseline at month 12 in Study 302 Part B; once daily patients gained 29.7, per the company.
How many Zolgensma patients developed tumors?
Nine, according to BioPharma Dive’s account of a Novartis statement, out of about 6,000 people treated. Two cases showed evidence of vector integration into DNA.
Is the FDA taking action on Zolgensma?
Per BioPharma Dive, the FDA said on November 6 it is investigating and evaluating whether regulatory action is appropriate, and that benefits still outweigh risks for approved uses.
Sources
Primary
- Unnatural Products and argenx, “Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next Generation Medicines,” GlobeNewswire release, Santa Cruz, November 9, 2026 (as carried by BioSpace)
- Novocure, “Novocure Provides Regulatory Update on US FDA Premarket Approval,” Business Wire, Baar, Switzerland, November 9, 2026 (investor.novocure.com)
- Veradermics, 12 month Study 302 release, Business Wire, New Haven, November 9, 2026 (as carried by BioSpace)
- Vir Biotechnology, ECLIPSE 1 topline release, Business Wire, November 8, 2026
- Settled exchange closes for November 6 and November 9, 2026
Trade press (attributed)
- BioPharma Dive, argenx and Unnatural Products deal report, November 9, 2026 (milestone figure, Leerink comment, Vyvgart sales context)
- BioPharma Dive, Vir hepatitis D Phase 3 report, November 9, 2026 (Evercore ISI comment, competitive context)
- BioPharma Dive, Zolgensma tumor report, November 6, 2026
- MedTech Dive, “Novocure denied FDA approval for metastatic cancer treatment,” November 9, 2026
- PharmTech, argenx deal report, November 9, 2026
